[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611913":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":10,"centralContacts":36,"locations":45,"responsibleParty":101,"collaborators":103,"id":110,"slug":111,"hasResults":112,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":112,"sex":118,"minAge":119,"maxAge":10,"enrollmentInfo":120,"targetDuration":10,"studyType":123,"phases":10,"briefSummary":124,"conditions":125,"keywords":131,"overallStatus":137,"whyStopped":10,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},{"fullName":5,"class":6},"OncoHost Ltd.","INDUSTRY",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with stage IV or stage III unresectable non-small cell lung cancer (NSCLC)",null,"Patients with stage IV or stage III unresectable non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors as a first-line treatment",[13],"Other: Blood sample collection",{"label":15,"type":10,"description":16,"interventionNames":17},"Patients with stage IV or stage IIIb-d malignant melanoma","Patients with stage IV or stage IIIb-d malignant melanoma treated with immune checkpoint inhibitors as a first-line treatment",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Patients with stage IV head and neck squamous cell carcinoma (HNSCC)","Patients with stage IV head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoint inhibitors as a first-line treatment",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Patients with stage IV renal cell carcinoma (RCC)","Patients with stage IV renal cell carcinoma (RCC) treated with immune checkpoint inhibitors as a first-line treatment",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Patients with stage IV triple-negative breast cancer (TNBC)","Patients with stage IV triple-negative breast cancer (TNBC) treated with immune checkpoint inhibitors as a first-line treatment",[13],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":10},"OTHER","Blood sample collection","Blood sample collection prior treatment initiation",[19,9,15,23,27],[37,42],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},"Michal Harel VP of Translational Medicine, PhD","CONTACT","97248537558","Michal@oncohost.com",{"name":43,"role":39,"phone":10,"phoneExt":10,"email":44},"Shani Raveh Shoval VP of Clinical Affairs, PhD","shani@oncohost.com",[46,64,81],{"facility":47,"status":10,"city":48,"state":10,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Heidelberg University Hospital","Heidelberg","69120","Germany","DE",{"type":53,"coordinates":54},"Point",[55,56],8.69079,49.40768,{"lat":56,"lon":55},[59,62],{"name":60,"role":39,"phone":10,"phoneExt":10,"email":61},"Petros Christopoulos","petros.christopoulos@gmail.com",{"name":60,"role":63,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":65,"status":10,"city":66,"state":10,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Intituto Europeo di Oncologia SRL","Milan","20121","Italy","IT",{"type":53,"coordinates":71},[72,73],12.59836,42.78235,{"lat":73,"lon":72},[76,79],{"name":77,"role":39,"phone":10,"phoneExt":10,"email":78},"Francesco Bertolini","francesco.bertolini@ieo.it",{"name":80,"role":63,"phone":10,"phoneExt":10,"email":10},"Bertolini Francesco",{"facility":82,"status":10,"city":83,"state":10,"zip":84,"country":85,"countryCode":86,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Virgen Macarena University Hospital - Servicio Andaluz de Salud","Seville","41071","Spain","ES",{"type":53,"coordinates":88},[89,90],-5.97317,37.38283,{"lat":90,"lon":89},[93,97,100],{"name":94,"role":39,"phone":95,"phoneExt":10,"email":96},"Alberto Moreno","+34 955057406","alberto.moreno.sspa@juntadeandalucia.es",{"name":98,"role":39,"phone":10,"phoneExt":10,"email":99},"Francisco J.","innovacion.hvm.sspa@juntadeandalucia.es",{"name":94,"role":63,"phone":10,"phoneExt":10,"email":10},{"type":102,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[104,106,108],{"name":105,"class":32},"European Institute of Oncology",{"name":107,"class":32},"University Hospital Heidelberg",{"name":109,"class":32},"Hospital Universitario Virgen Macarena","100611913","neutrophil-biomarker-test-for-predicting-clinical-benefit-from-immunotherapy-based-on-flow-cytometry-analysis-100611913",false,"NCT07246759","Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis","NEUTROFLOW: Development and Validation of a Pan-cancer Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis of Blood Samples","NEUTROFLOW","Inclusion Criteria:\n\n• Patients newly diagnosed with advanced-stage\u002Fmetastatic NSCLC, melanoma, HNSCC, RCC, or TNBC, who are due to receive first-line treatment with a PD-(L)1 inhibitor, either as monotherapy or in combination with other agents, according to current standard-of-care regimens, including (but not limited to) the following approved options: NSCLC. Monotherapy: Pembrolizumab, Atezolizumab, Cemiplimab. Combination: Pembrolizumab + chemotherapy; Nivolumab + Ipilimumab; Cemiplimab + chemotherapy; Atezolizumab + chemotherapy + Bevacizumab.\n\nMelanoma. Monotherapy: Nivolumab, Pembrolizumab. Combination: Nivolumab + Ipilimumab; Nivolumab + Relatlimab.\n\nHNSCC. Monotherapy: Pembrolizumab, Cemiplimab. Combination: Pembrolizumab + chemotherapy.\n\nRCC. Combination only: Nivolumab + Ipilimumab; Nivolumab + Cabozantinib; Pembrolizumab + Lenvatinib or Axitinib; Avelumab + Axitinib.\n\nTNBC. Combination only: Pembrolizumab + chemotherapy.\n\n* Male or female aged at least 18 years\n* ECOG PS: 0\u002F1-2\n* Normal hematologic, renal and liver function:\n\nAbsolute neutrophil count \\> 1500\u002Fmm³ Platelets \\> 100,000\u002Fmm³ Hemoglobin \\> 9 g\u002FdL Creatinine concentration ≤ 1.4 mg\u002FdL, or creatinine clearance \\> 40 mL\u002Fmin, Total bilirubin \\\u003C 1.5 mg\u002FdL ALT + AST levels ≤ 3 times above the upper normal limit\n\nExclusion Criteria:\n\n* Any concurrent and\u002For other active malignancy that has required systemic treatment within 2 years of the first dose of treatment.\n* For NSCLC: presence of activating EGFR, ALK, ROS1, RET, NTRK alterations linked to an approved first-line targeted drug.","ALL","18 Years",{"count":121,"type":122},600,"ESTIMATED","OBSERVATIONAL","The NeutroFlow study is a multi-center clinical trial designed to develop a computational model that converts flow cytometry results into a prediction of clinical benefit. The study analyzes Ly6Ehi neutrophils in biological samples from patients treated with immune checkpoint inhibitors to evaluate their likelihood of benefiting from treatment. Blood samples are collected prior to treatment and used to support the ongoing development of the algorithm.",[126,127,128,129,130],"Non Small Cell Lung Cancer (NSCLC)","Melanoma (Skin Cancer)","Triple Negative Breast Cancer (TNBC)","RCC, Renal Cell Cancer","HNSCC",[132,133,134,135,136],"Immunotherapy","Biomarker","Neutrophils","Flow Cytometry","Immune checkpoint inhibitor","NOT_YET_RECRUITING","2025-11-20",{"date":140,"type":141},"2025-11-24","ACTUAL",{"date":143,"type":122},"2025-11-15",{"date":145,"type":122},"2028-05-30",{"name":5,"class":6},3]